An unacceptable level of cardiovascular risk still remains prevalent in the UK – are we doing enough?

Statins represent the cornerstone of lipid-lowering therapy in patients with or at high risk of premature premature cardio vascular disease (CVD) but even among those that achieve guideline targets for low-density lipoprotein (LDL) cholesterol, there is still a 50–70% residual risk of cardiovascular events on statin monotherapy. In terms of absolute cardiovascular risk, nearly one in six statin-treated patients will experience an event over the next five years.